Top

Clinical Reviews in Allergy & Immunology

Published in:

01-02-2020 | Anakinra

Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

Authors: Sheng Li, Siting Zheng, Shunli Tang, Yunlei Pan, Shan Zhang, Hong Fang, Jianjun Qiao

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2020

Abstract

Adult-onset Still’s disease (AOSD) is a rare multisystem autoinflammatory disorder of unknown etiology. AOSD is generally characterized by high spiking fever, arthralgia or arthritis, skin rash, leukocytosis, and hyperferritinemia. Traditionally, AOSD has been treated with non-steroidal anti-inflammatory drugs, corticosteroids, and immunosuppressants. An increasing number of studies have shown that proinflammatory cytokines, such as interleukin-1β, -18, -6, and tumor necrosis factor-α, play key roles in AOSD and may serve as therapeutic targets. In the current review, we provided insights into the roles of these cytokines in the pathogenesis of AOSD and also provided a commentary on the clinical studies of biologic therapy against AOSD.

Bywaters EG (1971) Still’s disease in the adult. Ann Rheum Dis 30(2):121–133CrossRef

Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, Kojima M, Lin Y, Hashimoto S, Inaba Y, Minowa M, Aizawa S, Ichikawa Y, Miyasaka N (1997) Estimated prevalence and incidence of adult Still’s disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 7(4):221–225CrossRef

Asanuma YF, Mimura T, Tsuboi H, Noma H, Miyoshi F, Yamamoto K, Sumida T (2015) Nationwide epidemiological survey of 169 patients with adult Still’s disease in Japan. Mod Rheumatol 25(3):393–400. https://doi.org/10.3109/14397595.2014.974881 CrossRefPubMed

Evensen KJ, Nossent HC (2006) Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol 35(1):48–51. https://doi.org/10.1080/03009740510026616 CrossRefPubMed

Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, Broussolle C, Seve P (2014) Adult-onset Still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 93(2):91–99. https://doi.org/10.1097/MD.0000000000000021 CrossRef

Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, Ocal L, Aral O, Konice M (2009) Adult-onset Still’s disease. Int J Clin Pract 63(7):1050–1055. https://doi.org/10.1111/j.1742-1241.2007.01393.x CrossRefPubMed

Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19(3):424–430PubMed

Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, Rozenberg S, Piette JC, Bourgeois P (2002) Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore) 81(3):194–200CrossRef

Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, Koeger AC, Meyer O, Guillevin L, Piette JC, Bourgeois P (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol 28(2):322–329PubMed

10.

Lebrun D, Mestrallet S, Dehoux M, Golmard JL, Granger B, Georgin-Lavialle S, Arnaud L, Grateau G, Pouchot J, Fautrel B (2018) Validation of the Fautrel classification criteria for adult-onset Still’s disease. Semin Arthritis Rheum 47(4):578–585. https://doi.org/10.1016/j.semarthrit.2017.07.005 CrossRefPubMed

11.

Terkeltaub R, Esdaile JM, Decary F, Harth M, Lister J, Lapointe N (1981) HLA-Bw35 and prognosis in adult Still’s disease. Arthritis Rheum 24(12):1469–1472CrossRef

12.

Wouters JM, Reekers P, van de Putte LB (1986) Adult-onset Still’s disease. Disease course and HLA associations. Arthritis Rheum 29(3):415–418CrossRef

13.

Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, Suwa A, Hirakata M, Mimori T (2001) Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford) 40(12):1398–1404CrossRef

14.

Joung CI, Lee HS, Lee SW, Kim CG, Song YH, Jun JB, Chung WT, Choe JY, Kim TG, Yoo DH (2003) Association between HLA-DR B1 and clinical features of adult onset Still’s disease in Korea. Clin Exp Rheumatol 21(4):489–492

15.

Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D et al (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70(2):118–136CrossRef

16.

Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7):1369–1376. https://doi.org/10.1172/JCI2629 CrossRefPubMedPubMedCentral

17.

Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2009) Functional association of interleukin 18 gene -607 (C/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still’s disease. J Rheumatol 36(10):2284–2289. https://doi.org/10.3899/jrheum.090316 CrossRefPubMed

18.

Wang FF, Huang XF, Shen N, Leng L, Bucala R, Chen SL, Lu LJ (2013) A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther 15(3):R65. https://doi.org/10.1186/ar4239 CrossRefPubMedPubMedCentral

19.

Yashiro M, Furukawa H, Asano T, Sato S, Kobayashi H, Watanabe H, Suzuki E, Nakamura T, Koga T, Shimizu T, Umeda M, Nonaka F, Ueki Y, Eguchi K, Kawakami A, Migita K (2018) Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still’s disease. Medicine (Baltimore) 97(49):e13394. https://doi.org/10.1097/MD.0000000000013394 CrossRef

20.

Nonaka F, Migita K, Jiuchi Y, Shimizu T, Umeda M, Iwamoto N, Fujikawa K, Izumi Y, Mizokami A, Nakashima M, Ueki Y, Yasunami M, Kawakami A, Eguchi K (2015) Increased prevalence of MEFV exon 10 variants in Japanese patients with adult-onset Still’s disease. Clin Exp Immunol 179(3):392–397. https://doi.org/10.1111/cei.12463 CrossRefPubMedPubMedCentral

21.

Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P (2014) Adult-onset Still’s disease. Autoimmun Rev 13(7):708–722. https://doi.org/10.1016/j.autrev.2014.01.058 CrossRefPubMed

22.

Feist E, Mitrovic S, Fautrel B (2018) Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol 14(10):603–618. https://doi.org/10.1038/s41584-018-0081-x CrossRefPubMed

23.

Hsieh CW, Chen YM, Lin CC, Tang KT, Chen HH, Hung WT, Lai KL, Chen DY (2017) Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset Still disease. J Rheumatol 44(8):1142–1150. https://doi.org/10.3899/jrheum.161354 CrossRefPubMed

24.

Hu Q, Shi H, Zeng T, Liu H, Su Y, Cheng X, Ye J, Yin Y, Liu M, Zheng H, Wu X, Chi H, Zhou Z, Jia J, Sun Y, Teng J, Yang C (2019) Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease. Arthritis Res Ther 21(1):9. https://doi.org/10.1186/s13075-018-1800-z CrossRefPubMedPubMedCentral

25.

Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N (2010) Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol 37(11):2369–2376. https://doi.org/10.3899/jrheum.100247 CrossRefPubMed

26.

Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, Nahm DH, Park HS (2003) Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol 30(11):2422–2427PubMed

27.

Chen DY, Lan JL, Lin FJ, Hsieh TY (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol 31(11):2189–2198PubMed

28.

Mitrovic S, Fautrel B (2018) New markers for adult-onset Still’s disease. Joint Bone Spine 85(3):285–293. https://doi.org/10.1016/j.jbspin.2017.05.011 CrossRefPubMed

29.

Maria AT, Le Quellec A, Jorgensen C, Touitou I, Riviere S, Guilpain P (2014) Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13(11):1149–1159. https://doi.org/10.1016/j.autrev.2014.08.032 CrossRefPubMed

30.

Kim HA, Choi B, Suh CH, Han MH, Jung JY, Sayeed HM, Kim YW, Sohn S (2017) Highly expression of CD11b and CD32 on peripheral blood mononuclear cells from patients with adult-onset Still’s disease. Int J Mol Sci 18(1), 202. https://doi.org/10.3390/ijms18010202 CrossRef

31.

Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2010) The associations of circulating CD4+CD25high regulatory T cells and TGF-beta with disease activity and clinical course in patients with adult-onset Still’s disease. Connect Tissue Res 51(5):370–377. https://doi.org/10.3109/03008200903461462 CrossRefPubMed

32.

Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis 63(10):1300–1306. https://doi.org/10.1136/ard.2003.013680 CrossRefPubMedPubMedCentral

33.

Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39(6):1003–1018. https://doi.org/10.1016/j.immuni.2013.11.010 CrossRefPubMedPubMedCentral

34.

Afonina IS, Muller C, Martin SJ, Beyaert R (2015) Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity 42(6):991–1004. https://doi.org/10.1016/j.immuni.2015.06.003 CrossRefPubMed

35.

Schett G, Dayer JM, Manger B (2016) Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol 12(1):14–24. https://doi.org/10.1038/nrrheum.2016.166 CrossRefPubMed

36.

Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ, Kullberg BJ, Rubartelli A, van der Meer JW, Dinarello CA (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 113(10):2324–2335. https://doi.org/10.1182/blood-2008-03-146720 CrossRefPubMedPubMedCentral

37.

Zhou S, Qiao J, Bai J, Wu Y, Fang H (2018) Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review. Ther Clin Risk Manag 14:167–171. https://doi.org/10.2147/TCRM.S155488 CrossRefPubMedPubMedCentral

38.

Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA (2005) Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 52(6):1794–1803. https://doi.org/10.1002/art.21061 CrossRefPubMed

39.

Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN (2007) Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66(6):842–843. https://doi.org/10.1136/ard.2006.066381 CrossRefPubMedPubMedCentral

40.

Kotter I, Wacker A, Koch S, Henes J, Richter C, Engel A, Gunaydin I, Kanz L (2007) Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 37(3):189–197. https://doi.org/10.1016/j.semarthrit.2007.04.002 CrossRefPubMed

41.

Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loet X, Sibilia J, Societe Francophone pour la Rhumatologie et les Maladies Inflammatoires en P, Club Rhumatismes et I (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67(3):302–308. https://doi.org/10.1136/ard.2007.076034 CrossRefPubMed

42.

Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, Burmester GR (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann Rheum Dis 69(2):466–467. https://doi.org/10.1136/ard.2009.108068 CrossRefPubMed

43.

Laskari K, Tzioufas AG, Moutsopoulos HM (2011) Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther 13(3):R91. https://doi.org/10.1186/ar3366 CrossRefPubMedPubMedCentral

44.

Nordstrom D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kajalainen A, Brun JG, Proven A, Ljung L, Kautiainen H, Pettersson T (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol 39(10):2008–2011. https://doi.org/10.3899/jrheum.111549 CrossRefPubMed

45.

Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, Sibilia J, Bourgeois P, Fautrel B, Cri (2013) Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res 65(5):822–826. https://doi.org/10.1002/acr.21901 CrossRef

46.

Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Baldissera E, Dagna L (2015) Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol 44(4):309–314. https://doi.org/10.3109/03009742.2014.992949 CrossRefPubMed

47.

Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, Touitou I, Kone-Paut I, MsGobo CRI (2015) Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis 10:19. https://doi.org/10.1186/s13023-015-0228-7 CrossRefPubMedPubMedCentral

48.

Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, Castaneda S, Olive A, Riveros A, Velloso-Feijoo ML, Narvaez J, Jimenez-Moleon I, Maiz-Alonso O, Ordonez C, Bernal JA, Hernandez MV, Sifuentes-Giraldo WA, Gomez-Arango C, Galindez-Agirregoikoa E, Blanco-Madrigal J, Ortiz-Santamaria V, del Blanco-Barnusell J, De Dios JR, Moreno M, Fiter J, de los Riscos M, Carreira P, Rodriguez-Valls MJ, Gonzalez-Vela MC, Calvo-Rio V, Loricera J, Palmou-Fontana N, Pina T, Llorca J, Gonzalez-Gay MA (2015) Efficacy of Anakinra in refractory adult-onset Still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554. https://doi.org/10.1097/MD.0000000000001554 CrossRef

49.

Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Cantarini L, Cavallaro E, Cavalli G, Cerrito L, Cipriani P, Dagna L, Marchi G, Vita S, Emmi G, Ferraccioli G, Frassi M, Galeazzi M, Gerli R, Giacomelli R, Gremese E, Iannone F, Lapadula G, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Ruscitti P, Silvestri E, Stagnaro C, Talarico R, Tincani A, Viapiana O, Vitiello G, Fabris F, Bindoli S, Punzi L, Galozzi P, Sfriso P (2017) Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol 8:369. https://doi.org/10.3389/fphar.2017.00369 CrossRefPubMedPubMedCentral

50.

Neel A, Wahbi A, Tessoulin B, Boileau J, Carpentier D, Decaux O, Fardet L, Geri G, Godmer P, Goujard C, Maisonneuve H, Mari A, Pouchot J, Ziza JM, Bretonniere C, Hamidou M (2018) Diagnostic and management of life-threatening adult-onset still disease: a French nationwide multicenter study and systematic literature review. Crit Care 22(1):88. https://doi.org/10.1186/s13054-018-2012-2 CrossRefPubMedPubMedCentral

51.

Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar CS, Speziale A (2018) Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol 36(4):668–675PubMed

52.

Vitale A, Cavalli G, Colafrancesco S, Priori R, Valesini G, Argolini LM, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Sota J, Cavallaro E, Massaro MG, Ruscitti P, Cipriani P, De Marchi G, De Vita S, Emmi G, Ferraccioli G, Frassi M, Gerli R, Gremese E, Iannone F, Lapadula G, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Silvestri E, Stagnaro C, Talarico R, Tincani A, Viapiana O, Vitiello G, Galozzi P, Sfriso P, Gaggiano C, Rigante D, Dagna L, Giacomelli R, Cantarini L (2019) Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response. Front Pharmacol 10:296. https://doi.org/10.3389/fphar.2019.00296 CrossRefPubMedPubMedCentral

53.

Sfriso P, Bindoli S, Galozzi P (2018) Adult-onset Still’s disease: molecular pathophysiology and therapeutic advances. Drugs 78(12):1187–1195. https://doi.org/10.1007/s40265-018-0956-9 CrossRefPubMed

54.

Kontzias A, Efthimiou P (2012) The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum 42(2):201–205. https://doi.org/10.1016/j.semarthrit.2012.03.004 CrossRefPubMed

55.

Galozzi P, Baggio C, Bindoli S, Oliviero F, Sfriso P (2018) Development and role in therapy of canakinumab in adult-onset Still’s disease. Front Pharmacol 9:1074. https://doi.org/10.3389/fphar.2018.01074 CrossRefPubMedPubMedCentral

56.

Junge G, Mason J, Feist E (2017) Adult onset Still’s disease-the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum 47(2):295–302. https://doi.org/10.1016/j.semarthrit.2017.06.006 CrossRefPubMed

57.

Petryna O, Cush JJ, Efthimiou P (2012) IL-1 trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis 71(12):2056–2057. https://doi.org/10.1136/annrheumdis-2012-201409 CrossRefPubMed

58.

Kaplanski G (2018) Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev 281(1):138–153. https://doi.org/10.1111/imr.12616 CrossRefPubMed

59.

Girard C, Rech J, Brown M, Allali D, Roux-Lombard P, Spertini F, Schiffrin EJ, Schett G, Manger B, Bas S, Del Val G, Gabay C (2016) Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford) 55(12):2237–2247. https://doi.org/10.1093/rheumatology/kew300 CrossRef

60.

Maruyama J, Inokuma S (2010) Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 37(5):967–973. https://doi.org/10.3899/jrheum.090662 CrossRefPubMed

61.

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kotter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 77(6):840–847. https://doi.org/10.1136/annrheumdis-2017-212608 CrossRefPubMedPubMedCentral

62.

Kiltz U, Kiefer D, Braun J, Schiffrin EJ, Girard-Guyonvarc'h C, Gabay C (2018) Prolonged treatment with Tadekinig alfa in adult-onset Still’s disease. Ann Rheum Dis annrheumdis-2018-214496. https://doi.org/10.1136/annrheumdis-2018-214496 CrossRef

63.

Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265(3):621–636. https://doi.org/10.1042/bj2650621 CrossRefPubMedPubMedCentral

64.

Skiniotis G, Boulanger MJ, Garcia KC, Walz T (2005) Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol 12(6):545–551. https://doi.org/10.1038/nsmb941 CrossRefPubMed

65.

Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, Brem G, Meyer zum Buschenfelde KH, Rose-John S (1996) The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183(4):1399–1406. https://doi.org/10.1084/jem.183.4.1399 CrossRefPubMed

66.

Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16(5):448–457. https://doi.org/10.1038/ni.3153 CrossRefPubMed

67.

Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M (2012) IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 122(4):143–159. https://doi.org/10.1042/CS20110340 CrossRef

68.

Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A (2016) Cytokine profile in adult-onset Still’s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol 169:8–13. https://doi.org/10.1016/j.clim.2016.05.010 CrossRefPubMed

69.

Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, Pan F (2018) Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: a meta-analysis. Mod Rheumatol 28(5):849–857. https://doi.org/10.1080/14397595.2017.1416924 CrossRefPubMed

70.

Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N (2009) A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 19(1):69–72. https://doi.org/10.1007/s10165-008-0116-2 CrossRefPubMed

71.

Puechal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, Kahn JE, Lequen L, Longy-Boursier M, Perdriger A, Schaeverbeke T, Toussirot E, Sibilia J, Club Rhumatismes Et I (2011) Tocilizumab in refractory adult Still’s disease. Arthritis Care Res 63(1):155–159. https://doi.org/10.1002/acr.20319 CrossRef

72.

Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, Minota S, Ishigatsubo Y, Ota T, Takei S, Soejima S, Inoue H, Koarada S, Tada Y, Nagasawa K (2012) Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol 22(5):712–719. https://doi.org/10.1007/s10165-011-0569-6 CrossRefPubMed

73.

Cipriani P, Ruscitti P, Carubbi F, Pantano I, Liakouli V, Berardicurti O, Giacomelli R (2014) Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol 33(1):49–55. https://doi.org/10.1007/s10067-013-2381-5 CrossRefPubMed

74.

Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, Ablin J, Abu-Shakra M, Savargyl-Maman H, Padova H, Caspi D, Rosner I (2014) Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol 41(2):244–247. https://doi.org/10.3899/jrheum.130881 CrossRefPubMed

75.

Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olive A, Castaneda S, Gallego Flores A, Hernandez MV, Mata C, Ros Vilamajo I, Sifuentes Giraldo WA, Caracuel MA, Freire M, Gomez Arango C, Llobet J, Manrique Arija S, Marras C, Moll-Tuduri C, Plasencia-Rodriguez C, Rosello R, Urruticoechea A, Velloso-Feijoo ML, Del Blanco J, Gonzalez-Vela MC, Rueda-Gotor J, Pina T, Loricera J, Gonzalez-Gay MA (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheum 66(6):1659–1665. https://doi.org/10.1002/art.38398 CrossRef

76.

Bannai E, Yamashita H, Kaneko S, Ueda Y, Ozaki T, Tsuchiya H, Takahashi Y, Kaneko H, Kano T, Mimori A (2016) Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Mod Rheumatol 26(2):297–301. https://doi.org/10.3109/14397595.2014.899178 CrossRefPubMed

77.

Nishina N, Kaneko Y, Kameda H, Takeuchi T (2015) The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: a retrospective, single-center study. Mod Rheumatol 25(3):401–404. https://doi.org/10.3109/14397595.2014.973659 CrossRefPubMed

78.

Song ST, Kim JJ, Lee S, Kim HA, Lee EY, Shin KC, Lee JH, Lee KH, Choi ST, Cha HS, Yoo DH (2016) Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol 34(6 Suppl 102):S64–S71PubMed

79.

Li T, Gu L, Wang X, Guo L, Shi H, Yang C, Chen S (2017) A pilot study on tocilizumab for treating refractory adult-onset Still’s disease. Sci Rep 7(1):13477. https://doi.org/10.1038/s41598-017-13639-y CrossRefPubMedPubMedCentral

80.

Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T (2018) Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77(12):1720–1729. https://doi.org/10.1136/annrheumdis-2018-213920 CrossRefPubMed

81.

Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, Delbrel X, Fautrel B, Richez C, Schaeverbeke T, Truchetet ME (2019) Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 21(1):53. https://doi.org/10.1186/s13075-019-1838-6 CrossRefPubMedPubMedCentral

82.

Faustman D, Davis M (2010) TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 9(6):482–493. https://doi.org/10.1038/nrd3030 CrossRefPubMed

83.

Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745–756. https://doi.org/10.1038/nri1184 CrossRefPubMed

84.

Kraetsch HG, Antoni C, Kalden JR, Manger B (2001) Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis 60(Suppl 3):iii55–iii57PubMedPubMedCentral

85.

Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et I (2005) Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 64(2):262–266. https://doi.org/10.1136/ard.2004.024026 CrossRefPubMed

86.

Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, Weinblatt ME (2002) Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum 46(5):1171–1176. https://doi.org/10.1002/art.10231 CrossRefPubMed

Title: Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease
Authors: Sheng Li
Siting Zheng
Shunli Tang
Yunlei Pan
Shan Zhang
Hong Fang
Jianjun Qiao
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Anakinra
Targeted Therapy
Cytokines
Published in: Clinical Reviews in Allergy & Immunology / Issue 1/2020
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-019-08747-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis

Innate B Cells: the Archetype of Protective Immune Cells

Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review

Standardization of Autoantibody Testing in Autoimmune Hepatitis

Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents

Antinuclear Antibodies in Systemic Sclerosis: an Update

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage